ResearcherGuangdong Academy of Medical SciencesNo recent work listed

Sheng Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3526-7808; OpenAlex author ID A5100720110. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 2

Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper

Papers 2

Therapeutic Targets and Prognostic Biomarkers Among CXC Chemokines in Pancreatic Ductal Adenocarcinoma Microenvironment. First author DOI 10.1097/mpa.0000000000002178 ↗
Sclareolide enhances gemcitabine‑induced cell death through mediating the NICD and Gli1 pathways in gemcitabine‑resistant human pancreatic cancer. Co-author DOI 10.3892/mmr.2017.6182 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Zi Yin · 1 shared paper, 2022 · strength 0.33
- Paper Therapeutic Targets and Prognostic Biomarkers Among CXC Chemokines in Pancreatic Ductal Adenocarcinoma Microenvironment. DOI 10.1097/mpa.0000000000002178 ↗
Jianhua Zhang · 1 shared paper, 2017 · strength 0.09
- Paper Sclareolide enhances gemcitabine‑induced cell death through mediating the NICD and Gli1 pathways in gemcitabine‑resista… DOI 10.3892/mmr.2017.6182 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.